Sugi Predict

Sugi Predict / Compounds / SCHEMBL1810190

SCHEMBL1810190

SCHEMBL1810190

CC(C)(C)OC(=O)NCc1cc(C(=O)O)no1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 1/20 0.45
▸ HDAC6 Q9UBN7 4/20 0.44
▸ HDAC1 Q13547 3/20 0.44
▸ POLB P06746 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ KDM4A O75164 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ HDAC3 O15379 1/20 0.39
▸ HDAC10 Q969S8 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ SCD O00767 1/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CA14 Q9ULX7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4010124 0.87 NR1H4 (0.44) NR1H4HDAC6HDAC1POLBSMN1; SMN2
SCHEMBL27773505 0.87 NR1H4 (0.47) NR1H4HDAC6HDAC1POLBSMN1; SMN2
SCHEMBL2490157 0.86 HDAC6 (0.53) NR1H4HDAC6HDAC1POLBSMN1; SMN2
SCHEMBL8235172 0.84 EPHX2 (0.49) NR1H4HDAC6HDAC1POLBSMN1; SMN2
SCHEMBL30914650 0.84 KDM4A (0.42) NR1H4HDAC6HDAC1POLBSMN1; SMN2
SCHEMBL1178054 0.84 MAPT (0.43) NR1H4HDAC6HDAC1POLBSMN1; SMN2
SCHEMBL14090181 0.83 NR1H4 (0.42) NR1H4HDAC6HDAC1POLBSMN1; SMN2
SCHEMBL4015367 0.82 EPHX2 (0.52) NR1H4HDAC6HDAC1SMN1; SMN2KDM4A
SCHEMBL2123367 0.82 EPHX2 (0.41) NR1H4HDAC6HDAC1SMN1; SMN2KDM4A
SCHEMBL2121683 0.81 NPC1 (0.51) POLBRAB9ANPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3885340-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2024-11-27 — — EP disclosed
EP-3885340-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2021-09-29 — — EP disclosed
US-11046713-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2021-06-29 — — US disclosed
EP-3369732-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2021-05-26 — — EP disclosed
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2020-09-24 — — US disclosed
US-10711013-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2020-07-14 — — US disclosed
US-20190100536-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2019-04-04 — — US disclosed
US-10118933-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2018-11-06 — — US disclosed
EP-3369732-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2018-09-05 — — EP disclosed
EP-3056485-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2018-05-09 — — EP disclosed
WO-2011051540-A9 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-06-21 — — WO disclosed
US-7973061-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-07-05 — — US disclosed
WO-2011051540-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2011-05-05 — — WO disclosed
US-20100130471-A1 Renin Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-05-27 — — US disclosed
US-20100130471-A1 Renin Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-05-27 — — US disclosed
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 — — US disclosed
WO-2008124582-A1 RENIN INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-10-16 — — WO disclosed
US-20080234132-A1 Microcin B17 Analogs And Methods For Their Preparation And Use PLANT BIOSCIENCE LIMITED (GB) 2008-09-25 — — US disclosed
EP-1730128-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-12-13 — — EP disclosed
WO-2005097765-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234132-A1 Microcin B17 Analogs And Methods For Their Preparation And Use MCM3, MCM7, CCNB3 NR1H4 2945/4885HDAC6 1851/4885HDAC1 1997/4885
US-10118933-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG NR1H4 30/4885HDAC6 586/4885HDAC1 698/4885
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE ALK, BCL3, MCL1 NR1H4 2549/4885HDAC6 1698/4885HDAC1 1046/4885
US-10711013-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG NR1H4 30/4885HDAC6 586/4885HDAC1 698/4885
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG NR1H4 30/4885HDAC6 586/4885HDAC1 698/4885
US-20190100536-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG NR1H4 30/4885HDAC6 586/4885HDAC1 698/4885
US-11046713-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG NR1H4 30/4885HDAC6 586/4885HDAC1 698/4885
US-20100130471-A1 Renin Inhibitors ACE, REN, DNPEP NR1H4 962/4885HDAC6 1416/4885HDAC1 829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.